Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My comments were regarding the transition away from Lannett. That’s the fiscal reporting requirement for company’s Q1 performance. Partnership with Lannett terminates end of March (end of W4/fiscal year). There’s not much to report on prior to then other than readiness for the split.
Regardless of stock movement in April, up or down, unless the company divulges more information (rather unlikely), no one will know more until Q1 call in August.
Profitability will depend on many other factors, including 3rd party logistics, distribution, upfront cost for sales staff, etc. We won’t know anything until August call for Q1. YE call in June covers only through March 31st unless more is divulged, which is doubtful.
The good thing is we are building out the pipeline, albeit at a snail’s pace, where a pink sheet OTC stock isn’t realistic…unless Adderall transition away from Lannett is an absolute cluster.
It all depends on how big the reverse split will be.
They have had a second shift since Covid started for spacing.
Shareholder tax loss tally person
He can do private placement agreements where he sells some of his ownership to an investment fund. It’s not an all or nothing situation.
The fact that we’re on the OTC bulletin board alone deters most investment funds.
Let’s see how the transition fairs from Lannett to self-distribution. Flat sales means a potential nice pickup in overall margins & earnings.
It was in the seed investment stage just a few years ago. Not a big company.
No two acquisitions are the same. There are a myriad of complexities that make one acquisition target good for one company, but not the other. Europe generally has a much longer time horizon for payback. Not so much in the US.
It varies. I have seen 2-5 years. Depends on many factors. Never seen company willing to wait 10 years. Way too much risk with that time horizon.
We’re driving a pinto or chevy nova
Another ANDA fire sale? Solid ROI on expenses incurred I’m sure.
Elite -11.2% on news.
Should we divulge all the times Elite’s share price has gone down double digits? There isn’t enough room to write it.
I’m not invested in LCI and couldn’t care less.
Massive? So they sold an ANDA to a company the size of Elite that was a seed company just a few years ago.
Sure.
The benefit we Elite gets is the hope of Pyros selling vigabatrin so they can actually get some mfg rev. Another sweet partnership for the books.
That’s because unexpected news isn’t built into the forward looking multiple if it’s out of left field. The significant float from dilution is the anchor weighing us down.
There is no news expected that would drive share price north before end of year. I am eager to see drug filings that take place first half of next year. Let’s get that R&D train moving for good.
Avoiding R/S to get to Nasdaq organically is not an option.
It’s their progress and recent patent approvals for insulin glargine. Huge market. Has nothing to do with Elite.
Agreed. Still have big hurdles ahead of us with transition away from Lannett. We won’t know how that transition is really going until about this time next year.
Nov 15, 2013 closing price: 0.12
Nov 15, 2022 closing price: 0.03
Yes, and the gross profit target range is still horrendous draining further on cash reserves.
There is more selling due to company profit margins still reported as negative last quarter and no certain target on profitability. This date keeps getting pushed back. Company has a great product, but if they can’t sell profitably, it’s simply not a viable business. Throw in news on shelf filing as well, which doesn’t bode confidence in CEO’s statement that we have enough liquidity. Trust in the company is eroding and VLD is becoming a show me stock after multiple setbacks.
Would be great if Elite was able to drive revenue through international expansion. If Elite is receiving one-time payments, their current portfolio of products is performing even worse since Elite’s revenue performance was flat.
Read the footnotes. These are options awarded. Company leadership hasn’t bought company stock on the open market for several years.
Paid vs revenue accrual are 2 completely different things.
None, other than smaller more flexible funds, but aren’t worth pursuing. This is why company needs to get off OTC and do an R/S and small ongoing buyback beyond just R&D investment. Company has had to reinvent itself multiple times and is about to embark on another one April 1st without Lannett. We may not hear how that transition is being executed until August call for Q1 results.
Apparently didn’t translate to Elite as expected. Sales volume was flat according to Elite’s reporting.
Let’s whip out the bubbly to celebrate mediocrity.
Adderall is the majority if their revenue. Of course the majority of their mfg rev is driven by Adderall. 2 customers counted for 96% of Elite revenue. That is almost entirely Adderall.
Lol
They ALWAYS break down mfg vs licensing rev each and every quarter.
Interesting that Mfg fees were less than last year in period of Adderall shortage. Awesome.
When factoring in inflation, that is a loss in revenue.
There is nothing interesting about it. It’s all contractual including the PPS on which the options are based.
Why would Nasrat take Elite to Nasdaq when their primary drug revenue has significant uncertainty after Lannett agreement termination?
1 billion+ shares outstanding with no interest yet from investment funds is the issue. Company is making strides, but being on OTC will not get us out of this share price rut. All while who gets paid handsomely in shares while the price remains low year after year continuing dilution?
Per the post, clearly the purpose is to audit all items and individuals up Nasrat’s rear.
Considering there is a massive shortage of trailers to use - cost for 3PL is through the roof right now.